Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.

J Clin Oncol · 2024 · PMC11404760 · PMID 39038268

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The presence of any SLiM criteria showed a trend to a higher risk of biochemical progression (12 [38.7%] of 31 patients) compared with those without (18 [30.5%] of 59 patients), but the difference was not statistically significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.